## Bo R Rueda

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2150274/publications.pdf

Version: 2024-02-01

61857 69108 6,522 118 43 77 citations h-index g-index papers 119 119 119 9234 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells. Nature Medicine, 2005, 11, 992-997.	15.2	394
2	CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer. Stem Cells, 2009, 27, 2875-2883.	1.4	386
3	Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18708-18713.	3.3	381
4	Leptin Signaling Promotes the Growth of Mammary Tumors and Increases the Expression of Vascular Endothelial Growth Factor (VEGF) and Its Receptor Type Two (VEGF-R2). Journal of Biological Chemistry, 2006, 281, 26320-26328.	1.6	216
5	Endometrial Cancer in Women 40 Years Old or Younger. Gynecologic Oncology, 2001, 83, 388-393.	0.6	209
6	The corpus luteum: an ovarian structure with maternal instincts and suicidal tendencies. Frontiers in Bioscience - Landmark, 2002, 7, d1949.	3.0	159
7	Caspase-3 Gene Knockout Defines Cell Lineage Specificity for Programmed Cell Death Signaling in the Ovary*. Endocrinology, 2001, 142, 2468-2480.	1.4	156
8	HIFâ€1α and HIFâ€2α have divergent roles in colon cancer. International Journal of Cancer, 2009, 124, 763-771.	2.3	151
9	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nature Communications, 2015, 6, 7419.	5.8	149
10	Ovarian cancer stem cell markers: Prognostic and therapeutic implications. Cancer Letters, 2012, 322, 1-7.	3.2	148
11	Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Research, 2009, 11, R36.	2.2	138
12	Constitutive Activation of Beta-Catenin in Uterine Stroma and Smooth Muscle Leads to the Development of Mesenchymal Tumors in Mice1. Biology of Reproduction, 2009, 81, 545-552.	1.2	129
13	Ovarian cancer stem cells: Working towards the root of stemness. Cancer Letters, 2013, 338, 147-157.	3.2	122
14	Decreased Progesterone Levels and Progesterone Receptor Antagonists Promote Apoptotic Cell Death in Bovine Luteal Cells1. Biology of Reproduction, 2000, 62, 269-276.	1.2	112
15	Caspase-3 Is a Pivotal Mediator of Apoptosis during Regression of the Ovarian Corpus Luteum. Endocrinology, 2002, 143, 1495-1501.	1.4	112
16	Increased bax and Interleukin-1Î <sup>2</sup> -Converting Enzyme Messenger Ribonucleic Acid Levels Coincide with Apoptosis in the Bovine Corpus Luteum during Structural Regression1. Biology of Reproduction, 1997, 56, 186-193.	1.2	111
17	Evidence for Cancer Stem Cells in Human Endometrial Carcinoma. Cancer Research, 2009, 69, 8241-8248.	0.4	111
18	The Current Status of Evidence for and Against Postnatal Oogenesis in Mammals: A Case of Ovarian Optimism Versus Pessimism?1. Biology of Reproduction, 2009, 80, 2-12.	1.2	101

#	Article	IF	CITATIONS
19	Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle, 2008, 7, 242-249.	1.3	94
20	Microvascular endothelial cells of the corpus luteum. Reproductive Biology and Endocrinology, 2003, 1, 89.	1.4	92
21	Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. International Journal of Cancer, 2008, 123, 2782-2790.	2.3	86
22	Prolonging the female reproductive lifespan and improving egg quality with dietary omegaâ€3 fatty acids. Aging Cell, 2012, 11, 1046-1054.	3.0	86
23	Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 111-116.	3.3	85
24	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Research, 2021, 81, 158-173.	0.4	85
25	The Epidemiology and Genetics of Uterine Leiomyoma. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 34, 3-12.	1.4	75
26	Loss of Cables, a Cyclin-Dependent Kinase Regulatory Protein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer. Cancer Research, 2004, 64, 202-208.	0.4	72
27	Notch signaling in serous ovarian cancer. Journal of Ovarian Research, 2014, 7, 95.	1.3	71
28	Prostaglandin F2α Stimulates the Expression and Secretion of Transforming Growth Factor B1 Via Induction of the Early Growth Response 1 Gene (EGR1) in the Bovine Corpus Luteum. Molecular Endocrinology, 2008, 22, 403-414.	3.7	70
29	Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model. PLoS ONE, 2011, 6, e28077.	1.1	62
30	Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecologic Oncology, 2011, 121, 212-217.	0.6	61
31	Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research, 2012, 18, 3197-3206.	3.2	60
32	Signaling mechanisms in tumor necrosis factor alpha-induced death of microvascular endothelial cells of the corpus luteum. Reproductive Biology and Endocrinology, 2003, 1, 17.	1.4	58
33	Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecologic Oncology, 2017, 145, 446-452.	0.6	57
34	CD95 Rapidly Clusters in Cells of Diverse Origins. Cancer Biology and Therapy, 2003, 2, 392-395.	1.5	56
35	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist, 2015, 20, 1058-1068.	1.9	56
36	Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecologic Oncology, 2008, 111, 289-297.	0.6	55

#	Article	IF	CITATIONS
37	Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecologic Oncology, 2008, 110, 293-298.	0.6	53
38	Ablation of Leptin Signaling Disrupts the Establishment, Development, and Maintenance of Endometriosis-Like Lesions in a Murine Model. Endocrinology, 2008, 149, 506-514.	1.4	52
39	The <i>Cables1</i> Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 513-522.	1.8	52
40	Ultra-rapid vitrification of mouse oocytes in low cryoprotectant concentrations. Reproductive BioMedicine Online, 2010, 20, 201-208.	1.1	49
41	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Frontiers in Bioscience - Landmark, 2011, 16, 368.	3.0	49
42	A Human Papillomavirus-Independent Cervical Cancer Animal Model Reveals Unconventional Mechanisms of Cervical Carcinogenesis. Cell Reports, 2019, 26, 2636-2650.e5.	2.9	49
43	Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reproductive Biology and Endocrinology, 2010, 8, 147.	1.4	48
44	Putative Role of the Phosphatidylinositol 3-Kinase $\tilde{A}^{\sharp}$ ; $\frac{1}{2}$ ? $\frac{1}{2}$ ? $\frac{1}{2}$ ? $\frac{1}{2}$ ?Akt Signaling Pathway in the Survival of Granulosa Cells. Endocrine, 2000, 12, 315-321.	2.2	46
45	BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma. Cancer Research, 2010, 70, 7155-7165.	0.4	46
46	Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin. PLoS ONE, 2012, 7, e41593.	1.1	45
47	Progesterone receptor membrane component 1 deficiency attenuates growth while promoting chemosensitivity of human endometrial xenograft tumors. Cancer Letters, 2015, 356, 434-442.	3.2	45
48	Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. MAbs, 2017, 9, 615-627.	2.6	45
49	Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors. Cancer Biology and Therapy, 2016, 17, 262-271.	1.5	44
50	<scp>YAP</scp> 1― <scp>LATS</scp> 2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis. EMBO Reports, 2019, 20, .	2.0	44
51	Characterization of extracellular DDX4- or Ddx4-positive ovarian cells. Nature Medicine, 2015, 21, 1114-1116.	15.2	41
52	Ovarian cancer stem cells: What progress have we made?. International Journal of Biochemistry and Cell Biology, 2019, 107, 92-103.	1.2	41
53	PARP Inhibition Induces Enrichment of DNA Repair–Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells. Molecular Cancer Research, 2019, 17, 431-445.	1.5	40
54	Cooperative Expression of Monocyte Chemoattractant Protein 1 Within the Bovine Corpus Luteum: Evidence of Immune Cell-Endothelial Cell Interactions in a Coculture System1. Biology of Reproduction, 2005, 72, 1169-1176.	1.2	39

#	Article	IF	CITATIONS
55	Dendritic cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias secondary to dysregulation of TLR receptors. Journal of Reproductive Immunology, 2012, 94, 210-215.	0.8	38
56	MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?. Human Reproduction Update, 2014, 20, 670-687.	5.2	38
57	Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer. PLoS ONE, 2011, 6, e18202.	1.1	35
58	Stem Cell Contribution to Ovarian Development, Function, and Disease. Endocrinology, 2008, 149, 4307-4311.	1.4	34
59	Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth. Frontiers in Oncology, 2014, 4, 171.	1.3	34
60	Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecologic Oncology, 2014, 133, 346-352.	0.6	34
61	Prostaglandin F2alpha- and FAS-activating antibody-induced regression of the corpus luteum involves caspase-8 and is defective in caspase-3 deficient mice. Reproductive Biology and Endocrinology, 2003, 1, $15$ .	1.4	33
62	Prostaglandin F2α Represses IGF-I-Stimulated IRS1/Phosphatidylinositol-3-Kinase/AKT Signaling in the Corpus Luteum: Role of ERK and P70 Ribosomal S6 Kinase. Molecular Endocrinology, 2010, 24, 632-643.	3.7	33
63	Dendritic Cells Attenuate the Early Establishment of Endometriosis-Like Lesions in a Murine Model. Reproductive Sciences, 2014, 21, 1228-1236.	1.1	33
64	Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice. Oncotarget, 2017, 8, 7265-7275.	0.8	33
65	Characterization and Regulation of Type A Endothelin Receptor Gene Expression in Bovine Luteal Cell Types. Endocrinology, 1999, 140, 2110-2116.	1.4	32
66	Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome. PLoS ONE, 2012, 7, e30996.	1.1	32
67	The Cables Gene on Chromosome 18q Is Silenced by Promoter Hypermethylation and Allelic Loss in Human Colorectal Cancer. American Journal of Pathology, 2007, 171, 1509-1519.	1.9	30
68	Transient commensal clonal interactions can drive tumor metastasis. Nature Communications, 2020, 11, 5799.	5.8	30
69	Acid sphingomyelinase involvement in tumor necrosis factor Â-regulated vascular and steroid disruption during luteolysis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7670-7675.	3.3	29
70	HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecologic Oncology, 2015, 137, 160-166.	0.6	29
71	Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecologic Oncology, 2010, 119, 462-468.	0.6	28
72	Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartum. American Journal of Obstetrics and Gynecology, 2014, 210, 445.e1-445.e6.	0.7	28

#	Article	IF	CITATIONS
73	The Antiâ€Inflammatory Impact of Omegaâ€3 Polyunsaturated Fatty Acids During the Establishment of Endometriosisâ€Like Lesions. American Journal of Reproductive Immunology, 2014, 72, 392-402.	1.2	27
74	The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells. Cancers, 2019, 11, 1678.	1.7	26
75	Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma. PLoS ONE, 2018, 13, e0201314.	1.1	25
76	Loss of CABLES1, a Cyclin-dependent Kinase-interacting Protein that Inhibits Cell Cycle Progression, Results in Germline Expansion at the Expense of Oocyte Quality in Adult Female Mice. Cell Cycle, 2007, 6, 2678-2684.	1.3	24
77	Cables1 protects p63 from proteasomal degradation to ensure deletion of cells after genotoxic stress. EMBO Reports, 2010, 11, 633-639.	2.0	22
78	Adrenomedullin is a therapeutic target in colorectal cancer. International Journal of Cancer, 2014, 134, 2041-2050.	2.3	22
79	Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Journal of Ovarian Research, 2016, 9, 58.	1.3	22
80	MicroRNA 21a-5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma. Reproductive Biology and Endocrinology, 2018, 16, 46.	1.4	22
81	Understanding and Targeting Apoptotic Pathways in Ovarian Cancer. Cancers, 2019, 11, 1631.	1.7	22
82	Stress-induced mitogen-activated protein kinase signaling in the corpus luteum. Molecular and Cellular Endocrinology, 2000, 164, 59-67.	1.6	21
83	Loss of Cables, a Novel Gene on Chromosome 18q, in Ovarian Cancer. Modern Pathology, 2003, 16, 863-868.	2.9	21
84	Upregulation of MUC4 in Cervical Squamous Cell Carcinoma: Pathologic Significance. International Journal of Gynecological Pathology, 2009, 28, 127-133.	0.9	20
85	Dual HER2 Targeting Impedes Growth of <i>HER2</i> Geneâ€"Amplified Uterine Serous Carcinoma Xenografts. Clinical Cancer Research, 2014, 20, 6517-6528.	3.2	20
86	Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. Oncotarget, 2018, 9, 23289-23305.	0.8	20
87	Galectins and Ovarian Cancer. Cancers, 2020, 12, 1421.	1.7	18
88	Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Scientific Reports, 2021, 11, 3718.	1.6	18
89	Increased growth rate, Delayed senescense and decreased serum dependence characterize cables-deficient cells. Cancer Biology and Therapy, 2005, 4, 654-658.	1.5	16
90	Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biology and Therapy, 2008, 7, 180-188.	1.5	16

#	Article	IF	CITATIONS
91	Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model. Gynecologic Oncology, 2014, 133, 607-615.	0.6	16
92	Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biology and Therapy, 2005, 4, 110-114.	1.5	15
93	Metformin therapy in a hyperandrogenic anovulatory mutant murine model with polycystic ovarian syndrome characteristics improves oocyte maturity during superovulation. Journal of Ovarian Research, 2011, 4, 8.	1.3	15
94	The N-methyl-D-aspartate Receptor, a Precursor to N-methyl-D-aspartate Receptor Encephalitis, is Found in the Squamous Tissue of Ovarian Teratomas. International Journal of Gynecological Pathology, 2014, 33, 598-606.	0.9	15
95	Mouse models of uterine corpus tumors clinical significance and utility. Frontiers in Bioscience - Elite, 2010, E2, 882-905.	0.9	13
96	Cytokeratin 18 expression inhibits cytokine-induced death of cervical cancer cells. International Journal of Gynecological Cancer, 2010, 20, 1474-81.	1.2	10
97	<i>cables1</i> is required for embryonic neural development: molecular, cellular, and behavioral evidence from the zebrafish. Molecular Reproduction and Development, 2011, 78, 22-32.	1.0	9
98	MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma. Reproductive Biology and Endocrinology, 2016, 14, 45.	1.4	9
99	Mutant mouse models and their contribution to our knowledge of corpus luteum development, function and regression. Reproductive Biology and Endocrinology, 2003, 1, 87.	1.4	8
100	Reprogramming of ovarian granulosa cells by YAP1 leads to development of high-grade cancer with mesenchymal lineage and serous features. Science Bulletin, 2020, 65, 1281-1296.	4.3	8
101	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancers, 2020, 12, 1206.	1.7	6
102	Sunitinib reduces recurrent pelvic adhesions in a rabbit model. Journal of Surgical Research, 2012, 178, 860-865.	0.8	5
103	Evaluation of anastomotic strength and drug safety after short-term sunitinib administration in rabbits. Journal of Surgical Research, 2014, 187, 101-106.	0.8	5
104	CABLES1 Deficiency Impairs Quiescence and Stress Responses of Hematopoietic Stem Cells in Intrinsic and Extrinsic Manners. Stem Cell Reports, 2019, 13, 274-290.	2.3	5
105	Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development. Oncogene, 2022, 41, 3761-3777.	2.6	5
106	Ovine Prostaglandin F <sub>2<math>\hat{l}\pm</math></sub> Receptor: Steroid Influence on Steady-State Levels of Luteal mRNA. Endocrine, 1999, 10, 105-112.	2.2	4
107	The impact of vitrification on murine germinal vesicle oocyte In vitro maturation and aurora kinase A protein expression. Journal of Assisted Reproduction and Genetics, 2014, 31, 1695-1702.	1.2	4
108	Effect of sunitinib on functional reproductive outcome in a rabbit model. Fertility and Sterility, 2012, 98, 496-502.	0.5	3

#	Article	IF	CITATIONS
109	Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Gynecologic Oncology, 2016, 141, 570-579.	0.6	3
110	Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy. Cancer Research, 2022, 82, 773-784.	0.4	3
111	Surgical Debulking Before or After Chemotherapy: Stemming the Tide on Ovarian Cancer Recurrence. Onkologie, 2010, 33, 286-287.	1.1	1
112	No REST for fibroids. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1980-1981.	3.3	1
113	Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions. Cancers, 2021, 13, 2195.	1.7	0
114	Cables 1 Mediates Progesterone-Induced Inhibition of Endometrial Epithelial Cell Proliferation Biology of Reproduction, 2008, 78, 129-129.	1.2	0
115	Defining the Antagonistic Role of Omega-3 Polyunsaturated Fatty Acid in the Establishment and Early Maintenance of Endometriosis-Like Lesions in a Murine Model Biology of Reproduction, 2011, 85, 379-379.	1.2	0
116	Inhibition of gamma-secretase activity in combination with paclitaxel to reduce platinum-resistant ovarian tumor growth Journal of Clinical Oncology, 2013, 31, 5578-5578.	0.8	0
117	Targeting the PI3K signaling cascade in <i>PIK3CA</i> mutated endometrial cancer in a primary human xenograft model Journal of Clinical Oncology, 2013, 31, e13564-e13564.	0.8	0
118	Abstract 3390: Preliminary results for a novel single extracellular vesicle assay for early stage ovarian cancer: The power of co-localized detection of surface biomarkers. Cancer Research, 2022, 82, 3390-3390.	0.4	0